BridgeBio Announces FDA Acceptance and Priority Review of NDA for Oral Infigratinib in Achondroplasia

Regulatory Catalyst Overview

On October 6, 2026, BridgeBio Pharma, Inc. announced that the U.S. Food and Drug Administration (FDA) accepted for filing its New Drug Application (NDA) with Priority Review for oral infigratinib, an investigational FGFR3 inhibitor targeting achondroplasia in pediatric patients.

Key Highlights & Timeline

• Regulatory Designation: Priority Review granted, shortening standard review cycles due to high unmet medical need.
• PDUFA Date: February 4, 2027.
• Commercial Preparedness: BridgeBio reaffirmed readiness to execute a commercial launch in the U.S. immediately following approval.
• Ex-U.S. Expansion: BridgeBio plans to submit a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) in Q4 2026.

Pivotal Trial Performance (PROPEL 3)

• Primary Endpoint: Significant increase in annualized height velocity (AHV) at Week 52, showing a mean treatment difference of +2.10 cm/year ($p < 0.0001$) and LS mean difference of +1.74 cm/year.
• Secondary Endpoints: Statistically significant improvement in height Z-score ($p < 0.0001$).
• Additional Endpoints: Oral infigratinib is the first candidate to achieve statistically significant improvement in both body proportionality (mean difference of -0.05 in ages 3–8, $p < 0.05$) and arm span (+0.37 SD z-score, $p < 0.0001$) against placebo in a randomized achondroplasia trial.
• Safety: Well tolerated, with zero study drug-related discontinuations or serious adverse events reported.

Market Impact & Significance

This milestone is of high trading significance for $BBIO investors. Achondroplasia affects approximately 55,000 individuals across the U.S. and EU. Oral infigratinib provides a potentially differentiated non-injectable alternative to existing standard of care, offering significant competitive advantages if approved.